Acute myeloid leukemia (AML) is the most common type of acute leukemia among adults with almost 20,000 new cases reported in the US in 2020. With the identification of recurrent mutations and the development of novel agents, stratification has allowed for improvements in patient outcomes. In this podcast, Thomas Cluzeau, MD, PhD, of the Central University Hospital of Nice, Nice, France, Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, and Andrew Wei, MBBS, PhD, of Alfred Hospital and Monash University, Melbourne, Australia, discuss key updates in the AML field presented at EHA 2020.
The post Latest AML therapies: novel preparations and first in class agents appeared first on VJHemOnc.
